These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial. Brugaletta S; Gomez-Lara J; Bruining N; Radu MD; van Geuns RJ; Thuesen L; McClean D; Koolen J; Windecker S; Whitbourn R; Oberhauser J; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW EuroIntervention; 2012 Jul; 8(3):352-8. PubMed ID: 22130182 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436 [TBL] [Abstract][Full Text] [Related]
13. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532 [TBL] [Abstract][Full Text] [Related]
14. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial. Brugaletta S; Gomez-Lara J; Serruys PW; Farooq V; van Geuns RJ; Thuesen L; Dudek D; Koolen J; Chevalier B; McClean D; Windecker S; Smits PC; de Bruyne B; Whitbourn R; Meredith I; van Domburg RT; Sihan K; de Winter S; Veldhof S; Miquel-Hebert K; Rapoza R; Garcia-Garcia HM; Ormiston JA; Bruining N JACC Cardiovasc Interv; 2011 Dec; 4(12):1281-9. PubMed ID: 22192369 [TBL] [Abstract][Full Text] [Related]
15. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Brugaletta S; Heo JH; Garcia-Garcia HM; Farooq V; van Geuns RJ; de Bruyne B; Dudek D; Smits PC; Koolen J; McClean D; Dorange C; Veldhof S; Rapoza R; Onuma Y; Bruining N; Ormiston JA; Serruys PW Eur Heart J; 2012 Jun; 33(11):1325-33. PubMed ID: 22507972 [TBL] [Abstract][Full Text] [Related]
16. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495 [TBL] [Abstract][Full Text] [Related]
17. Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Gómez-Lara J; Brugaletta S; Diletti R; Gogas BD; Farooq V; Onuma Y; Gobbens P; Van Es GA; García-García HM; Serruys PW Catheter Cardiovasc Interv; 2012 May; 79(6):890-902. PubMed ID: 21523891 [TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study. Zeng Y; Cavalcante R; Tenekecioglu E; Suwannasom P; Sotomi Y; Collet C; Abdelghani M; Jonker H; Digne F; Horstkotte D; Zehender M; Indolfi C; Saia F; Fiorilli R; Chevalier B; Bolognese L; Goicolea J; Nie S; Onuma Y; Serruys PW; Int J Cardiovasc Imaging; 2017 Apr; 33(4):441-449. PubMed ID: 28012050 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884 [TBL] [Abstract][Full Text] [Related]
20. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]